SEGMENT INFORMATION (Tables)

12 Months Ended

Oct. 31, 2025


	For the Years Ended October 31,
	2025												2024
	Cancer Vaccines			CAR-T Therapies			Other			Total			Cancer Vaccines			CAR-T Therapies			Other			Total

Revenues	$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	-

Research & development expenses		3,121			1,950			-			5,071			3,748			2,648			-			6,396
General & administrative expenses		4,137			2,439			54			6,630			4,291			3,084			60			7,435
Total operating expenses		7,258			4,389			54			11,701			8,039			5,732			60			13,831

Loss from operations		(7,394	)		(4,453	)		(54	)		(11,701	)		(8,039	)		(5,732	)		(60	)		(13,831	)

Interest income		417			252			4			673			651			476			6			1,133

Net loss	$	(6,841	)	$	(4,137	)	$	(50	)	$	(11,028	)	$	(7,388	)	$	(5,256	)	$	(54	)	$	(12,698	)

Total operating expenses	$	7,258		$	4,389		$	54		$	11,701		$	8,039		$	5,732		$	60		$	13,831
Less non-cash stock-based compensation		(2,365	)		(1,435	)		(10	)		(3,810	)		(2,804	)		(1,966	)		(12	)		(4,782	)
Operating expenses excluding non-cash stock-based compensation (a non-GAAP measure)	$	4,893		$	2,954		$	44		$	7,891		$	5,235		$	3,766		$	48		$	9,049